BHIVA Abstracts Annual Conference 2016

52 downloads 406 Views 5MB Size Report
the era of highly-active antiretroviral therapy compared to the general population: .... phoneline (122%) and email (152%) services (Table 1). Online comments ...
Dis w il

cov

eyo nlin elib r

er

thi

sj

ou

rna

lo

ary .co m/ jo

urn

nlin

HIV

MEDICINE Volume 17, Supplement 1, April 2016 Abstracts of the 22nd Annual Conference of the British HIV Association (BHIVA) Manchester, UK 19–22 April 2016

EDITORS Brian Gazzard Jens Lundgren

al/

ea

hiv

t

Registration opens in May 2016

PRELIMINARY ANNOUNCEMENT BHIVA Autumn Conference 13–14 October 2016 including

CHIVA Parallel Sessions Friday 14 October 2016 Preceded by Seventh Annual BHIVA Conference for the Management of HIV/Hepatitis Co-infection Wednesday 12 October 2016

QEII Centre London Discounted registration rates available for non-consultant BHIVA members

n tio ta le di ab re ail cc av A D be CP ill w

www.bhiva.org

Oral Abstracts HIV Care and Service Development O1 Non-AIDS mortality among people diagnosed with HIV in the era of highly-active antiretroviral therapy compared to the general population: England and Wales, 1997–2012 S Croxford1, S Desai1, A Kitching1, M Kall1, M Edelstein1, A Skingsley1, V Delpech1 and A Sullivan2 1 Public Health England, London, UK; 2Chelsea and Westminster Hospital, London, UK Background: Since the introduction of highly-active anti-retroviral therapy (HAART) in the mid-90s, there has been a shift in causes of death among people with HIV from AIDS to non-AIDS. We examine non-AIDS mortality in England & Wales (E&W) among people diagnosed with HIV in the era of HAART and compare to the mortality of the general population. Methods: Follow-up data on a national cohort of adults (≥15 years) diagnosed with HIV between 1997 and 2012 in E&W, were linked to death records from the Office of National Statistics (ONS) to the end of 2012. Deaths were categorised using a modified CoDe protocol. To compare cohort mortality to the general population, standardised mortality ratios (SMR) were calculated, stratifying by sex and five-year age bands, using published ONS population denominator data. Results: Of the 83,276 people included in these analyses, 5302 (6.4%) had died by the end of 2012, representing a crude mortality rate of 119 per 10,000 pys. All-cause mortality of the cohort was over five times higher than that of the general population of the same sex and age structure (SMR 5.7; 95% confidence interval [CI]: 5.6–5.9). SMR was higher among women (SMR 9.0; 95% CI: 8.6–9.5) than men (SMR 4.9; 95% CI: 4.8–5.1). Mortality remained high after deaths due to AIDS were excluded (SMR 2.2; 95% CI: 2.1–2.3; men: SMR 2.0; 95% CI: 1.9–2.1; women: SMR 3.0; 95% CI 2.8–3.3). Non-AIDS conditions accounted for 42% (2017) of all deaths with a known cause (91%). The majority of non-AIDS deaths were due to malignancies (19%) followed by cardiovascular disease (CVD)/stroke (19%), infections (17%), liver disease (12%), accident/suicide (9.4%), substance misuse (6.0%) and other causes (17%). Compared to the general population, high mortality was observed among people diagnosed with HIV who died from non-AIDS infections (SMR 11; 95% CI: 9.8–12), liver disease (SMR 3.7; 95% CI: 3.3–4.2), substance misuse (SMR 2.6; 95% CI: 2.1–3.1) and CVD/stroke (SMR 1.7; 95% CI: 1.4–1.9). Late diagnosis (CD4